INDIAN DRUGMAKERS SHOULD EXPECT FDA INSPECTIONS
U.S. FDA’s Margaret Hamburg: No bull’s eye on Indian drug developers
By Mari Serebrov
Wednesday, February 26, 2014
A rash of recent inspections that led to FDA enforcement actions against a number of Indian biopharma companies doesn’t mean the U.S. agency is targeting drugmakers in that country.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.